Ibuprofen,
does it really help with Relief of pain and daily-life impairment from primary dysmenorrhea?
research showsIbuprofen is graded B because evidence consistently shows relief of primary-dysmenorrhea pain and pain-related impairment of daily function. The Cochrane review included 80 randomized trials and 5,820 participants overall, but the NSAID-versus-placebo pain-relief analysis contained 35 trials and favored NSAIDs with an odds ratio of 4.37. Six trials directly compared ibuprofen with placebo. A 2020 network meta-analysis of 35 trials and 4,383 participants estimated an odds ratio of 10.08 for ibuprofen versus placebo. Direct outcomes are strong, but many source trials were old or poorly reported, supporting B with 75 points.
ads claimMarketing can make a fast-acting tablet look like causal treatment or a solution for every kind of menstrual pain. The evidence directly supports short-term symptom relief in primary dysmenorrhea; new severe pain, heavy bleeding, pain with intercourse, fainting, or fever warrants evaluation.
Useful facts when choosing a product
- Ibuprofen is an NSAID that suppresses prostaglandin production and may work best when started at pain onset or before pain becomes severe. The product label and clinician instructions determine the dose and maximum daily amount.
- Over-the-counter and prescription products can differ in tablet strength and directions. Ibuprofen should not be layered with another NSAID such as naproxen or aspirin for pain relief.
- People with peptic ulcer or gastrointestinal bleeding, kidney disease, cardiovascular disease, NSAID-triggered asthma, or anticoagulant use should seek professional advice first.
- Unsupervised use during pregnancy, especially from 20 weeks onward, should be avoided because of fetal renal, amniotic-fluid, and later ductus-arteriosus risks.
What the research actually shows
The 2015 Cochrane review included 80 randomized trials comparing NSAIDs with placebo, another NSAID, or paracetamol; 35 trials informed the direct NSAID-versus-placebo pain-relief analysis, and six directly compared ibuprofen with placebo. Nie 2020 network-analyzed 35 randomized trials of five over-the-counter analgesics and estimated ibuprofen as superior to placebo and second in efficacy ranking. The 1980 Morrison triple-blind randomized crossover trial enrolled 55 women and had 51 completers; ibuprofen 400 mg outperformed placebo for pain relief, patient preference, rescue analgesic use, and maintenance of normal daily function. A small 2007 Dawood crossover trial also favored ibuprofen over placebo for pain.
Why this is classified as B (75)
Of 80 trials included by Cochrane, 35 informed NSAID-versus-placebo pain relief and six directly compared ibuprofen with placebo; a 35-trial network meta-analysis and a verified direct daily-function trial also support benefit. Old and inadequately reported source trials prevent A, yielding B with 75 points, slightly above naproxen B70.
Counterpoint. Ibuprofen is a reasonable first-line medicine for typical primary dysmenorrhea, but disabling recurrent pain or failure despite adequate use calls for diagnostic evaluation and consideration of hormonal or other treatment options.
Rejudgment record. New verdict — Applied B at 75, slightly above naproxen B70, because 35 of 80 Cochrane trials informed NSAID-versus-placebo pain relief, six directly compared ibuprofen with placebo, and network synthesis plus a verified functional trial were consistent, while old designs and inadequate reporting prevent A
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Relief of primary-dysmenorrhea pain | B | Direct pain outcomes improved consistently across multiple placebo-controlled trials and meta-analyses. |
| Relief of pain-related impairment in daily activities | B | Direct functional evidence is smaller than the pain evidence but shows improved maintenance of normal daily activity. |
| Superiority to placebo | B | Cochrane and ibuprofen-specific network estimates consistently favored ibuprofen over placebo. |
| Always superior to paracetamol | C | Class-level comparisons are favorable, but direct ibuprofen evidence is limited and does not establish universal superiority. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Marjoribanks J et al. 2015 | Cochrane systematic review and meta-analysis | 6 | Cochrane academic review; funding varied across source trials | Pain relief, activity restriction, and adverse events in primary dysmenorrhea | Across 35 NSAID-versus-placebo pain-relief trials, NSAIDs were superior (OR 4.37, 95% CI 3.76 to 5.09), with low certainty because of methods-reporting limitations. | Key large evidence synthesis |
| Nie W et al. 2020 | Network meta-analysis of over-the-counter analgesics | 4,383 | Chinese public and academic support; authors declared no conflicts | Pain relief and adverse events in primary dysmenorrhea | Ibuprofen was superior to placebo for pain relief (OR 10.08, 95% CI 3.29 to 30.85). | Direct synthesis for ibuprofen |
| Morrison JC et al. 1980 | Randomized triple-blind crossover placebo-controlled trial | 51 | Inadequately reported; older comparative drug trial | Pain relief, patient preference, rescue analgesic use, and ability to pursue normal daily function | Ibuprofen 400 mg was superior to placebo for pain relief and maintenance of normal daily function. | Verified randomized trial with a direct functional endpoint |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Ibuprofen x relief of pain and daily-life impairment from primary dysmenorrhea — Evidence Grade B·75. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/ibuprofen-primary-dysmenorrhea-pain-daily-activity/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.